Helix begins enrolment for third dose level cohort of phase I/II study of L-DOS47
Three patients enrolled in the second dose level cohort completed the first treatment cycle and well tolerated the L-DOS47 therapy. Patients to be enrolled in the third cohort
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.